Gina Mauro | Authors


Study Identifies Ideal Ixazomib Triplet Regimen for Newly Diagnosed Multiple Myeloma

April 15, 2021

Ixazomib plus cyclophosphamide, and dexamethasone elicited higher rates of efficacy compared with ixazomib/dexamethasone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma/

Lenalidomide Reduces Infection Mortality Rates in COVID-19-Positive Patients With Multiple Myeloma

April 13, 2021

Infection mortality rate were lower in patients with multiple myeloma who were coronavirus disease 2019 positive and received maintenance lenalidomide than those who did not receive lenalidomide, according to study results presented during the 2nd European Myeloma Network Meeting.

Voruciclib Demonstrates Preliminary Activity Alone or in Combination with Sotorasib or Adagrasib in KRAS+ Cancers

April 10, 2021

In preclinical models of KRAS-mutant cancer, voruciclib, a CDK9 inhibitor, showed early activity as monotherapy and when used in combination with sotorasib and adagrasib, according to findings presented during Week 1 of the 2021 AACR Annual Meeting.